Table 1. Baseline characteristics of study participants by tertiles of baseline plasma FGF-23 concentrations.
| Characteristic | FGF-23 (RU/ml) | p-value | ||
|---|---|---|---|---|
| ≤ 1,966 | 1,967 – 11,492 | > 11,492 | ||
| Age (years) | 61 ± 11 | 63 ± 12 | 57 ± 11 | 0.08 |
| BMI (kg/m2) | 26.3 ± 4.1 | 27.2 ± 4.9 | 25.8 ± 3.8 | 0.51 |
| Systolic blood pressure (mmHg) | 142.4 ± 21.5 | 143.0 ± 28.7 | 135.0 ± 24.8 | 0.47 |
| Serum hemoglobin (g/dl) | 12.0 ± 1.6 | 11.7 ± 1.8 | 11.8 ± 1.5 | 0.67 |
| Serum albumin (g/dl) | 3.8 ± 0.4 | 3.8 ± 0.4 | 3.8 ± 0.5 | 0.86 |
| Plasma iPTH (pg/ml) | 184 ± 153 | 257 ± 216 | 466 ± 456 | 0.0003 |
| Serum calcium (mg/dl) | 9.0 ± 0.7 | 9.1 ± 0.8 | 9.4 ± 0.7 | 0.09 |
| Serum phosphorus (mg/dl) | 5.0 ± 1.6 | 5.5 ± 1.7 | 6.4 ± 1.4 | 0.0008 |
| Plasma 25(OH)D (ng/ml) | 16.9 ± 9.7 | 19.5 ± 12.7 | 16.9 ± 9.6 | 0.84 |
| Plasma 1,25(OH)2D (pg/ml) | 13.2 ± 8.2 | 14.7 ± 8.5 | 16.4 ± 17.7 | 0.43 |
| Serum total cholesterol (mg/dl) | 157.8 ± 37.4 | 151.8 ± 38.7 | 143.9 ± 35.8 | 0.19 |
| Serum HDL-C (mg/dl) | 43.4 ± 12.6 | 40.7 ± 13.4 | 37.6 ± 10.1 | 0.15 |
| Serum LDL-C (mg/dl) | 85.0 ± 29.1 | 85.9 ± 35.6 | 78.8 ± 29.4 | 0.51 |
| Serum triglycerides (mg/dl) | 163.2 ± 174 | 149.2 ± 106 | 154.1 ± 117 | 0.90 |
| Serum baseline LV EF (%) | 50.3 ± 12.5 | 52.5 ± 13.6 | 47.5 ± 13.9 | 0.32 |
| Time on dialysis (months) | 21.9 ± 34.5 | 16.1 ± 19.5 | 56.4 ± 62.2 | < 0.0001 |
| Time from randomization to measurement of FGF-23 (days) | 106.3 ± 54.4 | 94.4 ± 8.5 | 92.9 ± 11.3 | 0.45 |
All values are reported as mean ± SD unless otherwise stated. FGF-23 = fibroblast growth factor 23; BMI= body mass index; iPTH = intact parathyroid hormone; 25(OH)D = 25-hhydroxyvitamin D; 1,25(OH)2D = 1,25-dihydroxyvitamin D; HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; LV = left ventricular; EF = ejection fraction.